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Abstract
Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide.
It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and
cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects
against established HPV infections and lesions. These concerns create a critical need for the development of
therapeutic strategies, such as vaccines, to treat these existing infections and diseases.
Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV
oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are
consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for
the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this
knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV
vaccine clinical trials.
Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat
existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV
vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated
diseases in the near future.
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Background
Cervical cancer is the fourth most common cancer
effecting women worldwide [1]. Human papillomavirus
(HPV) accounts for nearly all cases of cervical cancer
and is responsible for causing several other cancers
including: penile, vaginal, vulval, anal and oropharynx
including base of the tongue and tonsils [1–4]. There are
over 200 types of HPV [5], which are categorized into
high risk, and low risk groups according to their onco-
genic potential [6, 7]. Among high risk HPV types, type
16 and type 18 are the most common and carcinogenic.
Combined, these two HPV types are responsible for
about 70 % of cervical cancer cases [8].
Identifying HPV as the etiological factor for HPV-
associated malignancies has created the opportunity to
control those cancers through vaccination and other
therapeutic strategies [9]. Vaccines have been tradition-
ally used as a prophylactic measure against infectious
diseases. Several successful prophylactic HPV vaccines
have been developed targeting the major capsid protein
L1 of the viral particle (for review see [10, 11]). Prophy-
lactic vaccines have been successful at preventing
healthy patients from acquiring HPV infections as well
as previously infected patients from being re-infected;
however, they are not able to treat or clear established
HPV infections and HPV-associated lesions (for review
see [10, 12]). One potential treatment method that has
been explored to treat and clear existing HPV infections
and associated diseases are therapeutic HPV vaccines.
Unlike prophylactic HPV vaccines, which are used to
generate neutralizing antibodies against viral particles,
therapeutic HPV vaccines are used to stimulate cell-
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mediated immune responses to specifically target and
kill infected cells.
Most sexually active women will be infected by HPV
at some point in their life. For many women these infec-
tions remain asymptomatic and are cleared by the
immune system. However, some women can develop
persistent HPV infections, which may further develop
into low or high-grade cervical intraepithelial neoplasia
(CIN) and cervical carcinoma, or regress at any stage
[13, 14]. In many HPV-associated lesions that progress
into cancers, the HPV viral DNA genome are found to
be integrated into the host’s genome. This process often
leads to the deletion of many early (E1, E2, E4, and E5)
and late (L1 and L2) genes. The deletion of L1 and L2
during the integration process is what renders prophy-
lactic vaccines useless against HPV-associated cancers.
In addition, E2 is a negative regulator for the HPV onco-
genes E6 and E7. The deletion of E2 during integration
leads to elevated expression of E6 and E7 and is thought
to contribute to the carcinogenesis of HPV-associated
lesions (for review see [9, 15]). Oncoproteins E6 and E7
are required for the initiation and upkeep of HPV-
associated malignancies and are resultantly expressed
and present in transformed cells [16]. Furthermore,
therapeutic HPV vaccines targeting E6 and E7 can cir-
cumvent the problem of immune tolerance against self-
antigens because these virus encoded oncogenic proteins
are foreign proteins to human bodies. For these reasons
HPV oncoproteins E6 and E7 serve as an ideal target for
therapeutic HPV vaccines [12].
Although prophylactic HPV vaccines have been a huge
success and leap forward in the prevention of HPV in-
fections and HPV-associated diseases, there is still a
great HPV-associated disease burden worldwide. As
such, there is an urgent need to develop treatments for
the control and eradication of existing HPV infections
and associated diseases. Our review will cover various
therapeutic HPV vaccines in development for the treat-
ment of HPV infections and HPV-associated diseases,
including HPV-associated cancers. In addition, we will
focus on the findings of latest clinical trials on thera-
peutic HPV vaccines.
Types of therapeutic HPV vaccines
Several types of therapeutic vaccines have been devel-
oped and tested in preclinical and clinical trials, includ-
ing live vector, protein or peptide, nucleic acid, and
cell-based vaccines (for review see [16]). Importantly,
clinical trials are necessary to evaluate whether a thera-
peutic HPV vaccine is able to control HPV infections
and HPV-associated diseases in humans. The majority of
these vaccines target HPV oncoproteins E6 and E7 with
the aim to deliver E6 and E7 antigens in various forms
to antigen presenting cells (APCs) in order to activate
HPV antigen-specific CD8+ cytotoxic T cells or CD4+
helper T cells, respectively (Fig. 1). Importantly, E6 and
E7 antigens need to be processed and digested by pro-
teasomes into smaller peptides before they can be pre-
sented on the MHC class I molecule of the APCs for the
activation of CD8+ T cells. However, not all peptide frag-
ments from the antigenic proteins are loaded on MHC
molecules and recognized by antigen-specific T cells
[17]. Only a selected few of these short peptides contain
the sequence of antigenic fragments (epitopes) that can
bind to the MHC molecule with high affinity and subse-
quently interact with the T cell receptor (TCR) of
antigen-specific T cells to elicit an immune response
[18–20]. Most therapeutic vaccines have been designed
to elicit an immune response against the E7 antigen be-
cause it is better characterized immunologically than the
E6 antigen in preclinical models.
The following section discusses the characteristics of
various therapeutic HPV vaccines being developed and
tested. The section summarizes numerous recent clinical
trials that have been implemented using various types of
therapeutic HPV vaccines against HPV-associated le-
sions and malignancies. Table 1 summarizes the clinical
trials on therapeutic HPV vaccines described in this sec-
tion. In addition, Table 2 lists several ongoing clinical tri-
als evaluating the efficacy of therapeutic HPV vaccines
against HPV-associated diseases.
Live vector-based vaccines
Live vector-based vaccines are often categorized as
either bacterial or viral vectors depending on their vec-
tor platform. These vectors replicate within the body
and facilitate the spread of the antigen [12, 16]. Live
vector-based therapeutic HPV vaccines are highly
immunogenic and can induce strong cellular and
humoral immune responses (for review see [16]). They
can also deliver E6 and E7 antigens to APCs to stimulate
antigen presentation through MHC class I and II. Unfor-
tunately, live vector-based vaccines pose a potential
safety risk, particularly in immunocompromised individ-
uals [12]. Additionally, the immune response efficacy
after repeated immunization using the same vector is
limited [12, 21, 22].
Bacterial vectors Several bacterial vectors have been se-
lected for the development of therapeutic HPV vaccines
including Listeria monocytogenes, Lactobacillus lactis,
Lactobacillus plantarum, and Lactobacillus casei [23–26].
Listeria has been recognized as a promising vector because
of its ability to infect macrophages and secrete listeriolysin
O (LLO), a pore-forming toxin, to evade phagosomal lysis
[27]. Because it is able to evade phagosomal lysis, Listeria is
able to replicate in the cytoplasm of the host cell. This abil-
ity further allows the bacteria to be present in both
Yang et al. Journal of Biomedical Science  (2016) 23:75 Page 2 of 19
cytoplasm and endosomal compartments allowing the anti-
gen peptides in the bacteria to be presented on both MHC
class I to cytotoxic T cells and MHC class II to T helper
cells [12, 26, 28, 29].
The first clinical use of a listeria-based therapeutic
HPV vaccine was reported in 2009 [30]. The vaccine
Lm-LLO-E7 (also known as ADXs11-001 or ADXS-
HPV) contains prfA-defective Lm strain, transformed
with HPV16 E7 antigen and a fragment of nonhemolytic
LLO [31]. The phase I trial tested the safety of Lm-LLO-
E7 in 15 patients with metastatic, refractory, or recur-
rent advanced squamous cell carcinoma of the cervix.
Patients received the vaccine intravenously, followed by
IV supplementation of 500 mg of ampicillin 5 days after
vaccination, followed by a 10-day oral course of ampicil-
lin (500 mg). The vaccine was well tolerated by patients;
common adverse effects included pyrexia, vomiting,
chills, headache and anemia, nausea and tachycardia,
and musculoskeletal pain. Furthermore, six patients ex-
perienced vaccine-related grade 3 adverse events.
Peripheral blood mononuclear cells (PBMCs) were col-
lected from patients and tested, showing an increase in
E7-specific IFNγ + T cells in three patients after vaccin-
ation. Reduction in total tumor size was observed in four
patients, suggesting that Lm-LLO-E7 may have thera-
peutic effects in controlling cancer progression. The
therapeutic potential demonstrated by the Lm-LLo-E7
vaccine has prompt the scientists to plan and design
additional clinical trials to further determine the efficacy
of this vaccine, including a phase II trial in patients with
persistent, recurrent, loco-regional or metastatic anal
cancer or HPV+ squamous cell carcinoma of the rectum
(NCT02399813), a phase II trial in patients with HPV+
OPC before resection (NCT02002182), a phase I/II trial
in patients with locally advanced or metastatic cervical
or HPV+ head and neck cancer with or without
MED14736 chemobile treatment (NCT02291055), and a
phase II trial in patients with persistent or recurrent
squamous or non squamous cell carcinoma of the cervix
(NCT01266460).
Fig. 1 Immune activation by therapeutic HPV vaccination. Administration of varying therapeutic HPV vaccine types results in the delivery of
different forms of antigen into the body. DNA plasmids encoding HPV oncoproteins E6 and E7 can be transfected into dendritic cells through
DNA vaccines or infection of transformed live vector-based vaccines. These antigens are then transcribed into RNA; however, RNA can also be
introduced into the cell through RNA vaccines. Transcribed RNA is further translated into antigen proteins or long peptides. Antigen proteins or
long peptides can also be taken up by the dendritic cell through phagocytosis after administration of a protein-based or peptide-based vaccine.
These proteins or peptides are processed into short peptides by proteasomes and loaded onto an MHC class I molecule in the endoplasmic
reticulum (ER) to be presented to T cell receptors on CD8+ T cells. In addition, dendritic cells or tumor cells can be prepared ex vivo to express
target antigens on MHC class I molecules with necessary co-stimulatory molecules and be administered back into the body as whole cell-based
vaccines through adoptive transfer in order to prime T cells. On the other hand, the protein or peptide antigens taken up by the dendritic cell
can be degraded into smaller fragments by proteases in the endosome. The endosome containing the small antigenic peptides is then fused
with the exosome containing MHC class II molecule, during which the antigenic peptide is loaded onto the MHC class II molecule. The MHC
class II – antigenic peptide complex is then transported to the cell surface to be presented to T cell receptors on CD4+ T cells
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Table 1 Different forms of therapeutic HPV vaccines recently used in clinical trials
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of the cervix (15 patients)
Increase in E7-specific T cells
detected in PBMCs of three
patients.
Reduction in tumor size




muscle and skeletal pain.
[30]
GLBL101c HPV16-E7 Recombinant Lactobacillus
casei expressing modified
version of HPV16-E7
GENOLAC BL Corp Phase I/IIa in HPV16+ CIN3
patients (17 patients)
Significant increase in E7-CMI
in cervical vaginal tract.
9 patients experienced disease
regression to CIN2, and 5
further regressed to LSIL




TA-HPV HPV-16/18 E6/E7 Recombinant Vaccinia
virus
European Organization for
Research and Treatment of
Cancer (EORTC)
Phase I/II in patients with





in 28 % of participants (3 out
of 8). 2 patients showed tumor
free condition at 15 and





Phase I in patients with
clinical International
Federation of Gynecology
and Obstetrics (FIGO) stage
Ib or IIa cervical cancer
who will undergo radical
hysterectomy (29 patients)
After a single vaccination
HPV-specific CTLs were found
in 4 patients. 8 patients (28 %)
developed HPV-specific
serological responses.
Mild to moderate local
toxicity
[54]




neoplasia of up to 15
years duration (12 patients)
5 of 12 (42 %) patients showed
at least 50 % reduction in total
lesion diameter over 24 weeks
with 1 patient showing complete
regression of lesion. Overall,
83 % of women showed some
average decrease in lesion size
of 40 %. All patients showed an
increased IgG titer and T-cell
response to the vaccinia virus.
A local reaction at the
site of vaccination
between day 7–10 was




TG4001 HPV-16 E6/E7 Recombinant modified
vaccinia Ankara-expressing
HPV-16 E6, E7, and IL-2
Transgene/roche Phase I in HPV16+ CIN2/3
patients (21 patients)
Ten of 21 (48 %) showed
disease regression, HPV DNA
clearance in eight patients and
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HPV-induced AGIN (1176
90 % lesion clearance in
female treated patient and
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female patients and 180
male patients)
treated patients. Antibody and





HPV16-SLP HPV-16 E6/E7 Combination of nine




ISA Pharmaceuticals Phase II in patients with
HPV16+ VIN3 (20 patients)
15 patients had objective
clinical response at 12 months.
9 complete responses and 6
partial response. 85 % with
circulating HPV-16 specific






flu like symptoms, chills,
and tiredness.
[60]
Phase II study in patients
with HPV16+ HSIL
(9 patients)
All vaccinated patients showed
strong HPV-specific T cell
response after vaccination.
Change in patterns of immune
infiltrate.
Itching, redness, swelling,
and pain at injection site,
headache, diarrhea,
fatigue/dizziness, nausea,
chills, myalgia, rash, fever,
urticarial, edema.
[59]




9 patients with HPV-16 specific
immune response. Duration of
survival correlates with






Phase II in patients with
low-grade abnormalities
of the cervix (50 patients)
97 % of vaccinated patients












11 of 12 vaccinated patients
















Gliknik Inc. Phase I in patients with
recurrent/metastatic
squamous cell carcinoma
of the head and neck
(5 patients)
80 % of patients who received
four vaccinated developed T
cell and antibody response.
Progression free and overall
survival is 8- to 196 days
respectively
Erythema, itching, and








University of Arkansas Phase I study in patients
with biopsy-confirmed
HSIL (31 patients)










HPV18 E7 proteins fused
to catalytically inactive
Genticel Phase I trial in patients
positive for HPV-16 or
HPV-18 infection but with
Patients in cohort 4 (n = 9)

















Table 1 Different forms of therapeutic HPV vaccines recently used in clinical trials (Continued)
Bordetella pertussis CyaA





TA-CIN HPV-16 E6/E7/L2 HPV16 E6E7L2 fusion
protein
Xenova Research Limited Phase I in healthy patients
(40 subjects)
TA-CIN specific IgG in 24 of 32







Phase II with VIN2/3
patients (19 patients)
63 % lesion response 1 year
after vaccination. Significant
increase.











virus with HPV16/18 E6/E7
Celtic Pharma Phase I with HPV16+ VIN
patient (10 patients)
Partial or complete clinical
response in 2 patients. All but 1
patient showed HPV-16 specific
IgG and/or T cell responses.
Pain at injection site. [69]
Phase II with HPV16+
high-grade AGIN Patients
(29 patients)
17 patients showed TA-CIN
induced T cell responses. 11
generated HPV-16/18 E6 and/or
E7 specific T cells. 14 with IgG







HPV-16/18 E6/E7 Plasmid encoding
mutated form of HPV16-E7
linked to sig and HSP70





Phase I with HPV16+ CIN3
Patients (12 patients)
58 % vaccinated patients have
generated HPV-16 E7-specific








HPV-16 E7 Plasmid encoding
mutated form of




Phase I with HPV16+
CIN2/3 Patients
(32 patients)
30 % vaccinated patients
experienced histological
regression to CIN1 or less.
Increase in intraepithelial
C8+ T cells infiltrate after
vaccination.
Injection site reaction. [81]
GX-188E HPV-16/18 E6/E7 Plasmid encoding fusion
protein of HPV 16/18 E6/E7
linked to Flt3L and tpa






complete lesion regression by
the end of the trial.




VGX-3100 HPV-16/18 E6/E7 Mixture of two plasmids
encoding optimized
consensus of E6 and E7
antigen of HPV 16 and 18
Inovio Pharmaceuticals Phase I with
HPV16/18 + CIN2/3
Patients (18 patients)
HPV-specific CMI observed in
78 % patients and HPV-specific






HPV16/18 + CIN2/3 Patients
(167 patients)
49.5 % vaccinated patient
demonstrated regression

















Table 1 Different forms of therapeutic HPV vaccines recently used in clinical trials (Continued)
enhance T cell and humoral
response.
Whole Cell Based
DC + KLH HPV-16 and
HPV-18 E7
Dendritic Cells pulsed
with HPV-16 and HPV-18
E7 and keyhole limpet
hemocyanin
National Institutes of Health Phase I in patients with
stage Ib or IIa cervical
cancer (10 patients)
Increase in HPV-specific
humoral and CD4+ T cell
responses observed, but





DC HPV antigens DC pulsed with HPV+
tumor lysate
Department of
Biotechnology (DBT, Govt. of
India)
Phase I in in patients with
HPV+ advanced, recurrent
cervical cancer (14 patients)
No significant increase in
lymphocyte proliferation
observed. Lack of biopsy
sample and small sample
size prevent definite
conclusions.















Table 2 Ongoing therapeutic HPV vaccine clinical trials




Persistent HPV Infection and Low-Grade Squamous
Intraepithelial Lesion






PDS Biotechnology Corp. Phase I in female patients with high risk





ProCervix HPV-16/18 E7 2 recombinant
adenylate cyclase (CyaA)
proteins: CyaA-HPV
16E7 & CyaA-HPV 18E7
Genticel Phase II in female patients with
HPV16/18+ infection or ASCUS/LSIL
(220 estimated patients)
December 2016 NCT01957878





protein of HPV 16/18 E6/E7
linked to Flt3L and tpa
Genexine, Inc Phase II in HPV 16/18+ CIN2, CIN2/3, and
CIN3 patients in Eastern Europe (120
estimated patients)
December 2017 NCT02596243
Phase II in HPV 16/18+ CIN3 patients in South
Korea (72 estimated patients)
October 2016 NCT02139267
















HPV16-E7 linked to sig
and HSP70 and vaccinia
virus with HPV16/18 E6/E7
Phase I in patients with HPV16+ CIN3 in





HPV-16 E7 Fusion protein of
HPV-16 E7 and ER
targeting sequence
THEVAX Genetics Vaccine Co. Phase IIa in patients with HPV induced
cervical HSIL (51 estimated patients)
June 2017 NCT02576561




University of Arkansas Phase II in patients with cervical HSIL
(125 estimated patients)
August 2020 NCT02481414
Anal Intraepithelial Neoplasia (AIN)
ISA101
(SLP-HPV-01; HPV16-SLP)
HPV-16 E6/E7 Combination of nine





ISA Pharmaceuticals Phase I/II in HIV+ male patients with
HPV-16+ AIN2/3 (45 estimated patients)
February 2018 NCT01923116















encoding HPV-16 E7 antigen
fused to a fragment of
nonhemolytic listeriolysin O
(LLO)
Phase II trial in patients with persistent,
recurrent, loco-regional, or metastatic
anal cancer or HPV+ squamous cell
carcinoma of the rectum that are either
treatment naïve in the metastatic setting
or have progressed or become intolerant
to platinum based therapy (55 estimated
patients)
HPV-Associated Incurable Solid Tumors
ISA101
(SLP-HPV-01; HPV16-SLP)
HPV-16 E6/E7 Combination of nine HPV-16




ISA Pharmaceuticals Phase II in patients with HPV-16+ Incurable
solid tumors (oropharyngeal squamous cell
carcinoma, cervical, vulvar, vaginal, anal,
and penile cancer) as combination therapy
with Nivolumab (28 estimated patients)
December 2018 NCT02426892
DPX-E7 HPV-16 E7 HPV16-E711-19 nanomer Dana-Farber Cancer Institute Phase Ib/II trial in HLA-A*02 positive
patients with incurable HPV 16-related
oropharyngeal, cervical and anal cancer
(44 estimated patients)
May 2023 NCT02865135
Head and Neck Cancer
ADXS11-001 (Lm-LLo-E7) HPV-16-E7 prfA-defective Listeria
monocytogenes strain
transformed with plasmid
encoding HPV-16 E7 antigen
fused to a fragment of
nonhemolytic listeriolysin O
(LLO)
Advaxis, Inc. Phase II in patients with
HPV+ Oropharyngeal Squamous Cell
Carcinoma before robot-assisted resection
(30 estimated patients)
March 2017 NCT02002182
Phase I/II in patients with locally
advanced or metastatic cervical or








Mixture of three plasmids
encoding optimized
consensus of E6 and E7
antigen of HPV 16 and 18
and proprietary immune
activator expressing IL-12
Inovio Pharmaceuticals Phase I/IIA in patients with HPV
associated head and neck squamous cell
carcinoma (25 estimated patients)
December 2017 NCT02163057
Cervical Cancer
ADXS11-001 (Lm-LLo-E7) HPV-16-E7 prfA-defective Listeria
monocytogenes strain
transformed with plasmid
encoding HPV-16 E7 antigen
fused to a fragment of
nonhemolytic listeriolysin
O (LLO)
Advaxis, Inc. Phase II in patients with persistent or
recurrent squamous or non-squamous







Mixture of three plasmids
encoding optimized
consensus of E6 and E7
antigen of HPV 16 and 18
Inovio Pharmaceuticals Phase I/IIA in female patients with new,













Table 2 Ongoing therapeutic HPV vaccine clinical trials (Continued)
and proprietary immune
activator expressing IL-12
Phase II in patients with locally advanced
cervical cancer as combination therapy





HPV-16 E6/E7 Combination of nine
HPV-16 E6 and four HPV-16
E7 synthetic peptides with
incomplete Freund’s adjuvant
ISA Pharmaceuticals Phase I/II in female patients with
HPV-16+ advanced or recurrent cervical











Phase I in patients with HPV16 associated
cervical cancer (30 estimated patients)
May 2020 NCT02405221
AGIN Ano Genital Intraepithelial Neoplasia, AIN Anal intraepithelial Neoplasia, ASCUC atypical squamous cells of undetermined significance, CIN Cervical intraepithelial neoplasia, ER Endoplasmic reticulum, HIV Human











A recent study tested the efficacy and safety of oral ad-
ministration of GLBL101c, a bacterial vector-based
therapeutic HPV vaccine. The Phase I/IIa study involved
17 patients with HPV16+ CIN3 lesions [32]. GLBL101c
is generated from a recombinant L. casei that expresses
a modified HPV16-E7 antigen, which is no longer car-
cinogenic [23]. The bacterial vector-based vaccine was
administered to patients through ingestion after it was
made into powder and enclosed into capsule form. None
of the participating patients in this study experienced
serious adverse effects. A significant increase in E7-
specific cell-mediated immune responses in the cervical
vaginal tract was observed in all patients who received
the vaccine.
Other attenuated bacterial vectors can also be created
through transformation with plasmids containing the
genes of interest. For example, Salmonella, Shigella, and
Escherichia coli, can deliver plasmid encoding genes of
interest to APCs. Previous studies have tested the use of
Salmonella for the delivery of HPV16 E7 protein or E7
epitopes to elicit E7-specific responses [33].
Viral vectors Several viral vectors have been examined
to deliver HPV E6 and E7 antigens including adenovi-
ruses, adeno-associated viruses, alphaviruses, lentivirus,
and vaccinia viruses [16, 34–45].
Vaccinia virus is an enveloped, double-stranded DNA
virus belonging to the Poxvirus family. Vaccinia virus
has a large genome, highly infectious nature, and low
likelihood of unregulated integration of foreign DNA
into its genome, making it a promising viral vector for
vaccine delivery [46].
Several Modified Vaccinia Ankara (MVA)-based thera-
peutic HPV vaccines have been created and tested in
recent years. TG4001 is a suspension of MVATG8042
particles consisting of attenuated recombinant MVA in-
cluding sequences encoding modified HPV16 E6/E7 and
human IL-2. The safety and efficacy of this vaccine was
evaluated in 21 patients with HPV16-related CIN2/3
lesions [47]. Each patient received three subcutaneous
injections, at 1-week intervals of TG4001 in their thigh.
Most adverse effects were mild or moderate, including
inflammation, pruritus, edema at the injection site,
lymphadenopathy, fever, headache, asthenia, bone pain,
and vaginal discharge. Furthermore, HPV16 DNA clear-
ance was observed in 8 out of 10 responders, HPV16
mRNA clearance in 7, and no recurrence of high-grade
lesions was observed for 12 months after treatment.
Another MVA-based vaccine, MVA E2 was created to
deliver E2 proteins into vaccinated hosts rather than E6
and E7 [48]. The vaccine utilize the knowledge that E2
protein serve as inhibitor for the expression of E6 and
E7 oncoproteins, and that the introduction of E2 into
the host may suppress the activity of E6 and E7 in HPV-
infected host, and subsequently reduce the transforming
ability of the infected cells and the survivability of the
malignant, HPV-associated tumor cells [9, 15]. In
addition, E2 protein has been shown to arrest cell
growth and induce apoptosis of cancer cells [49]. In
addition, since some of the HPV-infected cells do not
experience the lost of E2 gene during the transformation
process (for review see [50–52]), MVA E2 vaccine may
also lead to the generation of CD8+ T cells that can tar-
get the E2 antigen expressing, HPV-infected cells. Thus,
MVA E2 may generate therapeutic antitumor effects
against HPV-associated lesions through immunologic
and biological mechanisms. MVA E2 was recently tested
in a phase III clinical study for the treatment of HPV-
induced ano-genital intraepithelial lesions [53], involving
a total of 1356 patients (both male and female). Patients
were injected locally at the lesion site or into visible
lesions. The overall efficacy in this study for treating
HPV-induced CIN lesions was around 90 % and all
males showed complete eradication of lesions. Addition-
ally, antibodies against HPV-E2 protein and MVA E2
vaccine were identified in the serum of all treated
patients and cytotoxic T cell response that are specific to
HPV-transformed cells were observed. The results of
this clinical study demonstrate the therapeutic potential
of the MVA E2 vaccine in treating HPV+ disease and
potentially stimulating the immune system to target
HPV-associated intraepithelial lesions.
TA-HPV is a live recombinant vaccinia virus vaccine
that encodes oncoproteins E6 and E7 of both HPV type
16 and HPV18. TA-HPV was first used in clinical trial in
eight patients with advanced stage cervical cancer [46].
In three patients’ TA-HPV induced an HPV-specific
cytotoxic T cell response, and two patients were tumor
free at 15 and 21 months after vaccination. In an add-
itional clinical study using TA-HPV, 8 out of 29 patients
displayed HPV specific serological responses, but HPV-
specific cytotoxic T cell response was short lived [54].
Another clinical trial administered TA-HPV to 12
patients with HPV16+ vulval intraepithelial neoplasia
(VIN) grade III and one patient with HPV16+ vaginal
intraepithelial neoplasia (VAIN) grade II [55]. A reduc-
tion in HPV-associated lesion size was observed in
patients as well as a significant increase in HPV16 E6/
E7-specific T cell response.
As mentioned earlier, one challenge to using live
vector-based therapeutic HPV vaccines is the generation
of antibacterial or antiviral immune responses and
neutralizing antibodies after initial vaccine exposure.
Consequently, this limits the efficacy of multiple vaccine
administrations. This issue was partially addressed by a
former study, which showed that cyclooxygenase 2
(COX-2) inhibitors may prevent the production of neu-
tralizing antibodies to vaccinia virus [56].
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Peptide and protein-based vaccines
Peptide and protein that are derived from HPV antigens
are processed by DCs and presented on either MHC
class I or class II molecules to stimulate CD8+ or CD4+
T cell immune response [12, 57]. Furthermore, peptide
and protein-based vaccines are safe, stable, and easy
to produce.
Peptide-based vaccines Although peptide-based vac-
cines are safe, stable, and easy to produce they have poor
immunogenicity and require lipids or other adjuvants,
such as chemokines, cytokines, and Toll-like receptor
(TLR) ligands, to enhance vaccine potency [57]. These
methods help improve the vaccine’s ability to activate
innate and adaptive immunity and further boost CD8+
T cell responses (for review see [12]). Unfortunately,
peptide-based vaccines are MHC specific, meaning that,
for the vaccine to be effective the specific immunogenic
epitopes of HPV antigens needs to be identified for each
individual. Due to the MHC specificity required of
peptide-based vaccines, they face certain challenges for
large scale production and treatment of HPV-associated
diseases [58]. One possible solution is the application
of overlapping long-peptide vaccines. This method
has been proven effective at inducing antigen-specific
T cell responses in several preclinical models, (for
review see [57, 58]).
HPV16 synthetic long-peptide vaccine (HPV16-SLP)
and its therapeutic effects have been studied extensively
in several clinical trials [59–61]. HPV16-SLP consists of
both E6 and E7 overlapping peptides and Montanide
ISA-51 as an adjuvant [62]. A recent placebo-controlled,
double-blinded phase II study further investigated the
capability of HPV16-SLP vaccines to establish long-term
immunologic memory in patients with low-grade abnor-
malities of the cervix [63]. In this study 50 patients were
randomly assigned to receive HPV16-SLP vaccination or
placebo, followed by a vaccine or placebo booster one
year later. Observed adverse effects included flu-like
symptoms and injection site reactions. 97 % of vacci-
nated patients showed a significant HPV16-specific
immune response and the study demonstrated that two
low-dose vaccinations of HPV16-SLP could induce a ro-
bust HPV16-specific T cell response, lasting up to one
year. Although clinical and virological responses were
not the objectives of the study, clinical regression and
viral clearance in several patients were observed.
Another study investigated whether HPV16-SLP
vaccination combined with standard carboplatin and
paclitaxel (CarboTaxol) chemotherapy could improve
immunity in patients with cervical cancer [64]. In
addition, this study sought to determine the time point
in which immunity is optimized and vaccine administra-
tion is most effective. Participating patients all had
advanced, recurrent, or metastatic cervical cancer but
were not required to have HPV16+ tumors. Patients
were divided into two cohorts. Six patients were
recruited for the first cohort and were administered Car-
boTaxol treatment once every three weeks for a total of
six CarboTaxol treatments to determine which time
point immunity is optimized. Levels of myeloid cells
dropped, reaching their lowest levels 1 to 2 weeks after
the second chemotherapy cycle in patients receiving
CarboTaxol treatment. Furthermore, the decrease in
myeloid cells corresponded with an increase in lymphoid
cells. Although the relative frequencies of CD4+ and
CD8+ T cells did not change, T cell function was en-
hanced. 13 patients and 19 healthy donors participated
in the second cohort, which looked at whether Carbo-
Taxol mediates normalizing of circulating immune cell
frequencies. 12 patients received a single vaccination of
HPV16-SLP 2 weeks after their second (n = 11) or third
(n = 1) chemotherapy cycle. During CarboTaxol treat-
ment lymphocyte count did not change; however, the
number of circulating leukocytes increased significantly.
Myeloid and lymphoid cell counts in CarboTaxol
patients reached levels close to normalized levels of
healthy donors. In addition, HPV16-SLP vaccination en-
hanced T cell response in patients, which remained the
same in 11 patients after six cycles of chemotherapy. Sig-
nificant regressions of tumors in patients were not
observed, and 1 patient died 11 weeks after vaccination
due to disease progression. However, vaccination was
well tolerated and most adverse events observed were
localized, injection site reactions. Additional clinical
studies are being conducted to continue to evaluate the
therapeutic potential of HPV-16 SLP vaccine. These in-
cludes a phase I/II trial in HIV+ male patient with HPV-
16+ AIN2/3 (NCT01923116), a phase II trial in patients
with HPV-16+ incurable solid tumors in combination
with Nivolumab (NCT02426892), and a phase I/II trial
in female patients with HPV-16+ advanced or recurrent
cervical cancer (NCT02128126).
PepCan is a therapeutic HPV vaccine consisting of
four synthetic peptides covering HPV16 E6 and Candin,
a novel adjuvant. The safety of PepCan was tested in a
phase I clinical trial study in 31 patients with high grade
squamous intraepithelial lesions (HSIL) [65]. PepCan
was administered intradermally every three weeks at 50,
100, 250, 500ug per peptide dose in six patients. 12 weeks
after the last injection a loop electric excision procedure
was performed to remove lesion tissues. In the final dose
portion of the phase I clinical trial an additional ten pa-
tients with biopsy-confirmed HSIL (any HPV type) were
vaccinated with 50ug per peptide dose. Common adverse
effects were mild to moderate injection site reactions,
with no dose-limiting toxicities reported. The 50ug per
peptide dosage demonstrated the best histological
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regression rate (50 % complete regression) and the most
significant virological response (85 % viral clearance).
Lastly, the viral load decreased in nine patients in whom
HPV infection was detected at entry and exit. A new
study is currently ongoing to further assess the efficacy
of Pepcan + candin vaccination regimen in a phase II
trial with cervical HSIL patients (NCT02481414).
Additionally, a phase I dose escalation trial using
therapeutic HPV-peptide based vaccine with adjuvant
Montanide and GMCSF (GL-0810) has been tested in
five patients with recurrent/metastatic (RM) squamous
cell carcinoma of the head and neck (SCCHN) [66].
GL-0810 was injected subcutaneously into participating
patients. Overall, the vaccine was well tolerated with
some adverse effects including erythema, pain, and
itching at injection site. Four patients (80 %) with
HPV16+ RM SCCHN generated T cell and antibody re-
sponses. Furthermore, no dose-limiting toxicities were
observed. This trial demonstrated that GL-0810 is able
to elicit an immune response and is well tolerated by
patients with late stage SCCHN.
In addition to the vaccine candidates described above,
a Phase I clinical trial has also been planned to evaluate
the safety and therapeutic effect of PDS0101, a new
therapeutic HPV vaccine candidate consist of Peptides
from HPV-16 E6 and E7 as antigen and R-enantiomer of
1,2-dioleoyl-3-trimethylammonium-propane chloride as
adjuvant, in female patients with high risk HPV infection
or CIN1 (NCT02065973). Furthermore, a phase Ib/II
trial has been planned to evaluate the therapeutic HPV
vaccine DPX-E7, a HPV16-E7 aa11-19 nanomer peptide
vaccine, in HLA-A*02 positive patients with incurable
HPV16-related oropharyngeal, cervical, and anal cancer
(NCT02865135).
Protein-based vaccines One benefit to using protein-
based vaccines is that they contain all human leukocyte
antigen (HLA) epitopes. This avoids the limitation of
MHC restriction, which is a setback to using peptide-
based vaccines [67]. Protein-based vaccines, however,
suffer from low immunogenicity and most are presented
through the MHC class II pathway which activates the
production of antibodies instead of generating a CTL re-
sponse [58]. Strategies to overcome these problems focus
on enhancing the MHC class I presentation. Adjuvants
and immunostimulating molecules are added to protein-
based vaccines to increase endogenous processing, to
further increase protein uptake by MHC class I, and to
effectively target to DCs, which increase MHC class I
presentation and activation of CD8+ T cells [57].
Therapeutic HVP vaccine TA-CIN is a subunit vaccine
encompassing HPV16 E6E7L2 fusion protein [68]. TA-
CIN has been proven immunogenic and safe in several
phase I/II clinical trials [69–71]. A phase II study tested
the ability of TA-CIN to be administered with imiqui-
mod, a topical immunomodulatory, to treat patients with
high grade vulva intraepithelial neoplasia (VIN) [72]. A
total of 19 patients received imiquimod 5 % cream and
three intramuscular TA-CIN vaccinations (128ug/time)
at 1-month intervals. Common adverse effects observed
after imiquimod cream application included local in-
flammation, ulceration, malaise, and flu-like symptoms;
however, no adverse effects associated with TA-CIN
were observed. Twenty weeks after vaccination an
increase in infiltrating CD8+ and CD4+ T cells were
observed, and at 52 weeks complete regression of VIN
was observed in 63 % of patients with 36 % of lesions
showed HPV16 clearance. In this study, antigen-specific
immune responses in patients correlated with lesion re-
gression. Currently, another Phase I study has been
planned to evaluate the safety and efficacy of TA-CIN in
combination with adjuvant GPI-0100 in patients with
HPV16 associated cervical cancer (NCT02405221).
GTL001 (ProCervix) is a therapeutic HPV protein-
based vaccine that targets both HPV type 16 and 18
[73]. GTL001 is composed of recombinant HPV16 and
HPV18 E7 proteins fused to catalytically inactive Borde-
tella pertussis CyaA expressed in E. coli. A phase I trial
was conducted to examine the safety, tolerability, and
immunogenicity of GTL001 in 47 women who had nor-
mal cytology but were positive for HPV16 or HPV18
infection. The participants were divided into four co-
horts with two placebo sub-cohorts included within
cohort three. Each patient was administered either
100ug or 600ug of GTL001 with imiquimod. Patients
treated with GTL001 experienced injection site reactions
including pain, swelling, induration, tenderness, and
itching; however, the study demonstrated that vaccin-
ation with GTL001 was relatively safe. GTL001 induced
a humoral response to CyaA in all subjects but anti-E7
antibodies were not induced. All patients showed similar
immunogenicity and tolerability. Patients in cohort 4
(n = 9) who received 600ug GTL001 powder + imiqui-
mod experienced the highest HPV16/18 clearance
rate. However, in the recently press release by GEN-
TICEL regarding their interim (18 months) results for
the double-blinded, placebo controlled, phase II studies
involving the use of GTL001 in 233 patients with HPV16/
18+ normal or abnormal cytology (NILM, ASCUS, or
LSIL) (NCT01957878), no significant difference in viral
clearance was observed in HPV-16/18 positive patients
receiving GTL001 vaccine versus placebo.
Additional clinical trials have been planned to test the
potential of other therapeutic HPV protein vaccine can-
didates. One of such include the use of TVGV-1, a
fusion protein of HPV-16 E7 antigen with ER targeting
sequence, in a phase IIa trial with HPV induced cervical
HSIL patients (NCT02576561).
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Nucleic acid-based vaccines
DNA vaccines DNA vaccines have risen in popularity as
an attractive and potentially effective approach for
antigen-specific immunotherapy. DNA vaccines are safe,
stable, easy to produce and can sustain antigen expres-
sion in cells for longer durations than RNA vaccines or
protein vaccines. Furthermore, they do not produce
neutralizing antibodies, which permits repeated vaccin-
ation [67]. There is a potential risk that administration
of DNA encoding HPV oncogenes E6 and E7 may lead
to cellular transformation. This problem was addressed
by modifying E6 and E7 DNA to result in subsequent
expression of proteins that are incapable of oncogenic
transformation [74]. DNA vaccines involve the injection
of plasmid DNA that encodes the antigen of interest, in
our case HPV E6 and E7, into the host’s cells.
DNA vaccines are often administered via intramuscular
(IM) injection; however, myocytes are usually the cells
that uptake the DNA after IM injection (for review see
[67]). Although myocytes will express the target antigen,
they are not professional APCs and therefore cannot ac-
tivate a robust immune response [75]. DCs play an im-
portant role in presenting the antigen to naïve CD8+
cytotoxic T cells and do so through either phagocytosis
and present exogenous antigen release from transfected
myocytes on MHC class I through cross presentation, or
direct transfection of DCs by vaccination leading to dir-
ect presentation to CD8+ T cells [76–78].
One limitation of DNA vaccines is that naked DNA is
unable to amplify and spread from transfected cells to
surrounding cells in vivo resulting in low immunogen-
icity. Consequently, several strategies have been devel-
oped to help overcome this hurdle (for review see [16]).
Therapeutic HPV DNA vaccines have undergone
many clinical trials to evaluate the efficacy and safety of
these vaccines. One such trial treated patients with
HPV16-associated CIN2/3 lesions with heterologous
prime-boost vaccination [79]. The DNA vaccine used in
this study was pNGVL4a-sig/E7(detox)/HSP70, a plas-
mid encoding mutated form of HPV16-E7 linked to
signal peptide and heat shock protein 70. pNGVL4a-sig/
E7(detox)/HSP70 DNA vaccine was previously shown to
enhance the HPV-16 E7 antigen-specific T cell mediated
immune responses in a preclinical model [80]. This
study also used TA-HPV vaccine as a booster. Twelve
patients received two intramuscular injections of
pNGVL4a-sig/E7(detox)/HSP70 boosted with TA-HPV,
at 1 month intervals. Reported adverse effects included
tenderness, local reaction at injection site, blister with
drainage, erythema, and pruritus. This study suggested
that local immune responses are ultimately responsible
for the therapeutic effects against target lesions and can
lead to better clinical outcomes. The prime boost regi-
men of pNGVL4a-sig/E7(detox)/HSP70 DNA + TA-HPV
viral vector vaccines is continued to be examined in a
phase I trial in combination with topical imiquimod ap-
plication in HPV16+ CIN3 patients (NCT00788164).
A more recent clinical study was conducted to evaluate
the safety, efficacy, and immunogenicity of pNGVL4a-
CRT/E7(detox), a DNA plasmid vaccine [81]. pNGVL4a-
CRT/E7(detox) was administered to 32 patients with
HPV16-associated CIN2/3 either intradermal, intramus-
cularly, or directly into the cervical lesion (intralesionally)
three times at four week intervals. This study demon-
strated that pNGVL4a-CRT/E7(detox) was well tolerated
in patients, and vaccination via intralesional injection
elicited stronger immune response and induced more
CD8+ T cells. Another phase I trial on pNGVL4a-CRT/
E7(detox) DNA vaccine is still currently ongoing
evaluating its safety and immunogenicity in patients
with HPV16+ CIN2/3 lesions (NCT00988559).
A phase I clinical trial was conducted to evaluate the
safety and efficacy of GX-188E, a therapeutic HPV DNA
vaccine. The study was conducted in nine patients with
high grade squamous intraepithelial lesions (HSIL/CIN3)
[82]. GX-188E is a DNA vaccine engineered to express
HPV16 and HPV18 proteins E6/E7 fused to the extracel-
lular domain of Flt3L and signal sequence of plasmino-
gen activator (tpa). Flt3L and tpa were included to
enhance the potency of the vaccine through trafficking
promotion and presentation of the fusion protein to the
secretory pathway. Nine patients were administered GX-
188E through intramuscular injection followed by elec-
troporation to enhance immunogenicity. The results of
this study demonstrated GX-188E to be safe and well
tolerated by patients. Furthermore, all patients showed a
statistically significant cellular immune response and
three patients showed a weak antibody response against
E7 protein. Genexine, Inc has planned two additional
clinical trials on GX-188E, including a Phase II trial to
be conducted in Eastern Europe targeting patients
with HPV16/18+ CIN2, CIN2/3, or CIN3 lesions
(NCT02596243), as well as a phase II trial to be con-
ducted in South Korea targeting patients with HPV
16/18+ CIN3 lesions (NCT02139267).
An additional clinical study tested the therapeutic ef-
fects of HPV DNA vaccine VGX-3100. VGX-3100 is a
combination of two plasmids encoding optimized
HPV16 and 18 E6 and E7 antigens [83, 84]. VGX-3100
was administered through intramuscular injection
followed by electroporation to 18 female patients who
had been previously treated for CIN2/3 lesions [85].
Each patient received three rounds of vaccination, which
was well tolerated with no observed dose-limiting toxic-
ities. Adverse effects included injection site reaction,
fever, pain during electroporation, and tenderness. Four-
teen out of 18 patients (78 %) showed induced HPV-
specific CD8+ T cells with full cytolytic function, 17 out
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of 18 (94 %) of patients had increased HPV16 E7 anti-
body titers, and all patients had increased HPV18 E7
antibody titers. Additionally, 12 patients (67 %) had in-
creased HPV16 E6 antibody titers, and seven (39 %)
patients had increased HPV18 E6 titers. These results
exhibited the potential of VGX-3100 to induce a robust
antigen-specific immune response and contribute to the
eradication of HPV-infected cells and lesion regression.
Furthermore, the results of this phase I study encour-
aged a follow up phase IIb clinical trial to further inves-
tigate the therapeutic efficacy of VGX-3100 DNA
vaccine on CIN 2/3 lesions in a randomized, double-
blind, placebo-controlled study [86]. This study corres-
pondingly demonstrated that patients vaccinated with
VGX-3100 showed greater HPV-specific T cell and
humoral responses. Inovio Pharmaceuticals has recently
designed a new vaccine formulation INO-3112, incorp-
orating the proprietary immune activator expressing IL-
12 (INO-9012) with the VGX-3100 DNA vaccine. This
formulation is being tested in a phase I/IIA trial in pa-
tients with HPV associated head and neck squamous cell
carcinoma (NCT02163057), a phase I/IIA trial in female
patients with new, recurrent, or persistent cervical
cancer (NCT02172911), as well as a phase II trial in
patients with locally advanced cervical cancer who re-
ceived standard of care chemoradiation (NCT02501278).
RNA vaccines Naked RNA replicon vaccines can be de-
rived from several RNA viruses including Sindbis virus,
Venezuela Equine Encephalitis virus, and SFV [34, 87, 88].
RNA replicons are capable of self-replication, which can
lead to a sustained level of antigen expression and in-
creased immunogenicity. Furthermore, RNA replicon vec-
tors do not form viral particles, meaning they will not lead
to the generation of neutralizing antibodies, permitting
repeated administration. RNA replicons are also highly ad-
vantageous vaccination methods because they do not run
the risk of chromosomal integration and cellular trans-
formation that can occur by using DNA vaccines. One
drawback to RNA replicons, however, is their low stability.
One attempt to overcome this issue combined RNA repli-
cons and DNA vaccine into DNA-launched RNA repli-
cons, which are also referred to as ‘suicidal DNA.’ These
‘suicidal DNA’ trigger apoptosis in cells that uptake the
injected DNA to prevent further integration and trans-
formation of transfected cells [89]. However, because it
will elicit apoptosis in transfected cells, including DCs,
this approach has led to poor immunogencity. Several
strategies have been created to address this issue. One ex-
ample is the inclusion of genes encoding anti-apoptotic
protein into ‘suicidal DNA’ to enhance survival of trans-
fected APCs [90]. Another strategy employed to overcome
apoptosis is the use of flavivirus Kunjin (KUN) vector to
deliver replicons. Since KUN does not induce apoptosis
in transfected cells, it enables the direct presentation
by transfected DCs [91, 92]. Although RNA replicon
vaccines have shown promising results in preclinical
models and in other types of cancer setting [93],
RNA vaccines targeting HPV antigens and HPV-
associated diseases have not yet been explored in the
clinical setting.
Whole cell-based vaccines
Dendritic cell-based vaccines DCs play an important
role in immune system regulation, and they are com-
monly identified as the most efficient professional APCs
[67]. DC-based vaccines have grown as the biological
knowledge of DC and methods for preparing DCs ex
vivo have improved. DC-based HPV vaccines involve
loading the DCs with HPV antigens ex vivo and deliver-
ing those DCs to the infected host [94–98]. One benefit
of DC-based vaccines is that DCs can serve as natural
adjuvants to increase the potency of antigen-specific
immunotherapy against cancer (for review see [99]). Be-
cause T cell-mediated apoptosis may limit DC lifespans,
some strategies have been developed to prolong the sur-
vival of DCs. One such strategy is to transfect DCs with
siRNAs targeting pro-apoptotic molecules. These strat-
egies have been shown to generate a greater antigen-
specific CD8+ T cell activation and antitumor effects in
mice [95, 97, 100].
Due to the therapeutic potential demonstrated by DC-
based vaccines in preclinical models, further clinical tri-
als were developed to test DC-based vaccine efficacy in
humans. One such study was conducted to evaluate
safety, toxicity, and immunogenicity of a DC-based vac-
cine in ten patients with stage Ib or IIa cervical cancer
[101]. In this phase I, dose escalation trial autologous
DCs were obtained from patients and pulsed with full
length HPV16/18-E7 oncoprotein and keyhole limpet
hemocyanin (KLH). The patients were then vaccinated
with the pulsed DCs through subcutaneous injection.
The DC-based vaccine used in the study was reported
safe and well tolerated by patients, and resulted in minor
local reactions, including erythema, swelling, and prur-
itus. There was an increase in HPV-specific humoral
response and an increase in E7-specific CD4+ T cells in
patients after vaccination.
An additional phase I clinical trial investigated the tox-
icity and immunogenicity of a DC-based vaccine in 14
patients with HPV+ advanced, recurrent cervical cancer
[102]. Patients were separated into three treatment
groups: saline only control, unprimed mature DC, and
autologous tumor lysate primed mature DC. DCs were
collected from each patient and pulsed with or without
tumor lysate obtained from the same patient. Grade 0
and grade 1 toxicity, including itching at vaccination site,
fever, chills, abdominal discomfort, and vomiting, were
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observed in three of the 14 patients, implying that the
DC-based vaccine was well tolerated. No statistically
significant increase in lymphocyte proliferation was ob-
served in all patient groups.
In congruence with other vaccine types, DC-based
vaccines have several limitations. DC-based vaccines are
technically taxing, thus making them a poor choice for
large-scale production. In addition, varying culturing
techniques may lead to inconsistent vaccine quality and
lack of standard criteria for vaccine evaluation. Lastly,
the most effective administration route for DC-based
vaccines has not yet been determined.
Tumor cell-based vaccines To create tumor cell-based
vaccines, tumor cells are isolated and manipulated ex
vivo to express immune modulatory proteins, which can
further enhance their immunogenicity in vivo. Cytokine
genes IL-2, IL-12, and granulocyte macrophage colony
stimulating factor (GMCSF) have been used to induce
differentiation of naïve T cells into effector or helper T
cells and to stimulate granulocyte production in HPV
tumor cell-based vaccines in mice with HPV16 induced
tumors [103, 104]. One advantage to tumor cell vaccines
is that tumor antigens do not need to be well defined;
therefore, these vaccines may be able to cover a wider
range of tumor antigens. Since HPV has well-known
tumor-specific antigens, tumor cell-based vaccines may
not be the most practical immunotherapy for HPV-
associated cancers. In addition, tumor cell-based vac-
cines run the risk of implanting new cancers in patients.
Due to the nature of these vaccines and their potential
risks, the potency and purity of each vaccine must be in-
dividually tailored, making production expensive and
time consuming. For these reasons tumor cell-based vac-
cines targeted against HPV have not yet been developed
and tested in clinical studies.
Conclusion
The identification of high-risk HPV as the etiological
factor for many diseases provides justification for the
development of therapeutic HPV vaccines. The recent
developments in the field as well as those discussed in
this review have helped contribute to the foundational
movement to eradicate HPV and HPV-associated dis-
eases and malignancies. In this review we discussed the
various methods of targeting HPV oncoproteins E6 and
E7, which represent tumor-specific antigens and excel-
lent targets for therapeutic HPV vaccines. Based on our
own previous studies, and those conducted by other in-
vestigators in the field, we believe that the current thera-
peutic HPV vaccines mentioned in this review each
possess advantages and limitations. Additional clinical
studies are still necessary to further verify the antitumor
efficacy of therapeutic HPV vaccines.
With continued efforts to improve and develop thera-
peutic treatment strategies, we anticipate the continued
success of therapeutic HPV vaccines over the next few
years, and beyond. We believe that therapeutic HPV vac-
cines will become clinically available in the near future
and be offered alongside other available therapies for the
control of HPV-associated diseases.
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